Travere’s FSGS therapy trial fails to meet primary efficacy endpoint

Travere Therapeutics has reported that the Phase III DUPLEX trial of sparsentan to treat patients with focal segmental glomerulosclerosis (FSGS), a rare kidney disease, failed to achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment.